Zealand Pharma reports positive phase III results against congenital hyperinsulinism
In a phase III study of dasiglucagon, biotech firm Zealand Pharma has met its endpoint, reducing the need for children under 12 months with the rare disorder to undergo intensive hospital treatment by 55%.
by marketwire, translated by daniel pedersen
On Thursday, Zealand Pharma has announced positive topline results from a phase III trial of dasiglucagon, a treatment for congenital hyperinsulinism (CHI), the firm reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand Pharma sells insulin pump to Mannkind Corporation
For subscribers
Zealand Pharma rescue pen books USD 0.6m revenue in Q1
For subscribers
.jpg&w=384&q=75)
